---
title: 'Medicine üçä‚≠ê'
date: 2023-01-03
permalink: /other/medicine
tags:
  - other
toc: true
---

Essences of clinical medicine.

{% include toc %}

# Cardiology / Âæ™Áí∞Âô®Áßë

# Pulmonology/ ÂëºÂê∏Âô®Áßë

## Respiratory Failure / ÂëºÂê∏‰∏çÂÖ®

### Respiratory Failure / ÂëºÂê∏‰∏çÂÖ®

* **Overview**
  * Inability of respiratory system to maintain adequate gas exchange, resulting in hypoxemia (Type I) and/or hypercapnia (Type II)
  * Can occur at any age, various underlying causes (pneumonia, COPD, pulmonary edema, etc.)
  * May present acutely or develop chronically, can be life-threatening without prompt treatment
* **Presentation**
  * **Dyspnea, tachypnea, use of accessory muscles**: Compensatory response to inadequate gas exchange and increased work of breathing
  * **Cyanosis (central and peripheral)**: Inadequate oxygenation leading to increased deoxygenated hemoglobin
  * **Altered mental status, confusion, somnolence**: Hypoxemia and hypercapnia affecting cerebral function
* **Examination**
  * **[ABG] PaO2 < 60 mmHg (Type I), PaCO2 > 45 mmHg (Type II), pH changes**: Direct measurement of gas exchange failure
  * **[Pulse oximetry] SpO2 < 90%**: Non-invasive assessment of oxygenation status
  * **[Chest X-ray/CT] Pulmonary infiltrates, pleural effusion, pneumothorax**: Identify underlying pulmonary pathology
* **Management**
  * **Oxygen therapy (nasal cannula, face mask, high-flow)**: Improve oxygenation and tissue oxygen delivery
  * **Non-invasive ventilation (BiPAP, CPAP)**: Support ventilation while avoiding intubation
  * **Mechanical ventilation (invasive)**: Provide complete respiratory support in severe cases
  * **Treat underlying cause (antibiotics, bronchodilators, diuretics)**: Address specific etiology causing respiratory failure
{: .notice--info}


### Acute Respiratory Distress Syndrome (ARDS) / ÊÄ•ÊÄßÂëºÂê∏Á™ÆËø´ÁóáÂÄôÁæ§

* **Overview**
  * Non-cardiogenic pulmonary edema due to increased pulmonary capillary permeability from inflammatory response triggered by direct or indirect lung injury
  * Commonly in ICU settings with various precipitating factors (sepsis, pneumonia, trauma, aspiration)
  * Acute onset with rapid progression, high mortality rate (30-40%)
* **Presentation**
  * **Severe dyspnea, tachypnea**: Impaired gas exchange due to alveolar epithelial/endothelial damage and ventilation-perfusion mismatch
  * **Hypoxemia refractory to supplemental oxygen**: Intrapulmonary shunting through flooded alveoli and ventilation-perfusion mismatch
  * **Cyanosis, restlessness**: Severe hypoxemia and hypoxia
* **Examination**
  * **[ABG] PaO2/FiO2 ratio <300 (mild), <200 (moderate), <100 (severe), initially respiratory alkalosis then metabolic acidosis**: Impaired oxygenation and CO2 retention
  * **[CXR] Bilateral pulmonary infiltrates**: Non-cardiogenic pulmonary edema
  * **[CT] Bilateral ground-glass opacities, consolidation, dependent atelectasis**: Inflammatory fluid accumulation and alveolar collapse
  * **[Echocardiography] Normal left atrial pressure, PCWP <18 mmHg**: Rule out cardiogenic pulmonary edema
* **Management**
  * **Mechanical ventilation with lung-protective strategy**: Prevent ventilator-induced lung injury while maintaining adequate ventilation
  * **Positive end-expiratory pressure (PEEP)**: Recruit collapsed alveoli and improve oxygenation
  * **Prone positioning**: Improve ventilation-perfusion matching in posterior lung regions
  * **Treat underlying cause (antibiotics for sepsis, supportive care)**: Address precipitating factors
{: .notice--info}


## Obstructive Lung Disease / ÈñâÂ°ûÊÄßËÇ∫ÁñæÊÇ£

### Asthma / ÂñòÊÅØ

* **Overview**
  * Chronic inflammatory airway disease characterized by reversible airway obstruction, airway hyperresponsiveness, and airway remodeling
  * Common in children and adults, often associated with atopy and family history of allergic diseases
  * Chronic condition with episodic exacerbations triggered by allergens, infections, exercise, or irritants
* **Presentation**
  * **Wheezing, shortness of breath, chest tightness**: Bronchoconstriction and airway narrowing due to smooth muscle contraction and mucosal edema
  * **Dry cough (often worse at night or early morning)**: Airway inflammation and hyperresponsiveness to stimuli
  * **Exercise intolerance**: Exercise-induced bronchoconstriction due to airway cooling and drying
  * **Symptom variability**: Symptoms fluctuate with triggers and time
* **Examination**
  * **[Pulmonary Function Test] FEV1‚Üì, FEV1/FVC ratio‚Üì, reversibility >12% after bronchodilator**: Airway obstruction that improves with bronchodilation
  * **[Peak Flow] Reduced peak expiratory flow rate, diurnal variation >20%**: Variable airway obstruction throughout the day
  * **[Blood] Eosinophilia, elevated total IgE, specific IgE to allergens**: Allergic inflammation and type I hypersensitivity reaction
* **Management**
  * **Short-acting Œ≤2-agonists (SABA)**: Relax bronchial smooth muscle for quick relief of bronchoconstriction
  * **Inhaled corticosteroids (ICS)**: Reduce chronic airway inflammation and prevent exacerbations
  * **Long-acting Œ≤2-agonists (LABA) + ICS combination**: LABA provides sustained bronchodilation, ICS controls inflammation
  * **Leukotriene receptor antagonists (LTRA)**: Block inflammatory mediators, especially useful in aspirin-sensitive or exercise-induced asthma
  * **Anti-IgE therapy**: Bind free IgE for severe allergic asthma
  * **Allergen avoidance, trigger identification**: Prevent exposure to known triggers to reduce exacerbation frequency
{: .notice--info}


### COPD (Chronic Obstructive Pulmonary Disease) / ÊÖ¢ÊÄßÈñâÂ°ûÊÄßËÇ∫ÁñæÊÇ£

* **Overview**
  * Progressive airway obstruction due to chronic inflammation, usually from smoking
  * Includes emphysema (alveolar destruction) and chronic bronchitis (airway inflammation and mucus hypersecretion)
  * Commonly in older adults, especially smokers and those with occupational dust exposure
  * Progressive, irreversible course with acute exacerbations
* **Presentation**
  * **Dyspnea (initially on exertion, progressing to rest), exercise intolerance**: Airway obstruction and impaired gas exchange reduce oxygen delivery
  * **Chronic productive cough with sputum**: Chronic bronchitis component causes mucus hypersecretion and impaired clearance
  * **Barrel chest, use of accessory muscles, pursed-lip breathing**: Hyperinflation and increased work of breathing due to air trapping
  * **Weight loss (advanced cases)**: Increased metabolic demand from respiratory work and systemic inflammation
* **Examination**
  * **[Physical] Decreased breath sounds, wheezing, hyperresonance**: Airway obstruction and hyperinflation
  * **[Pulmonary Function] FEV1/FVC < 0.7, TLC‚Üë, RV‚Üë**: Airway obstruction and air trapping
  * **[Chest X-ray/CT] Hyperinflation, flattened diaphragm, bullae**: Emphysematous changes and air trapping
  * **[ABG] PaO2‚Üì, PaCO2‚Üë (advanced)**: Ventilation-perfusion mismatch and alveolar hypoventilation
* **Management**
  * **Smoking cessation**: Prevent further lung damage and slow disease progression
  * **Short-acting bronchodilators (SABA, SAMA)**: Relieve acute bronchospasm by Œ≤2-agonism and anticholinergic action
  * **Long-acting bronchodilators (LABA, LAMA)**: Maintain bronchodilation and reduce exacerbations
  * **Inhaled corticosteroids (ICS)**: Reduce airway inflammation, especially in frequent exacerbators
  * **Oxygen therapy (long-term)**: Correct hypoxemia and prevent cor pulmonale in severe cases
  * **Pulmonary rehabilitation**: Improve exercise tolerance and quality of life through physical training
  * **[Acute exacerbation] Systemic corticosteroids, antibiotics, non-invasive ventilation**: Reduce inflammation, treat bacterial infection, support ventilation
{: .notice--info}


### Bronchiectasis / Ê∞óÁÆ°ÊîØÊã°ÂºµÁóá

* **Overview**
  * Irreversible dilation and distortion of bronchi and bronchioles due to chronic infection and inflammation, leading to impaired clearance mechanisms
  * Can be congenital (cystic fibrosis, primary ciliary dyskinesia) or acquired (post-infectious, immune deficiency, aspiration)
  * Progressive chronic condition with recurrent exacerbations
* **Presentation**
  * **Chronic productive cough with purulent sputum, recurrent respiratory infections**: Impaired mucociliary clearance and bacterial colonization in dilated airways
  * **Dyspnea on exertion, wheezing**: Airflow obstruction due to bronchial wall thickening and secretions
  * **Hemoptysis**: Chronic inflammation leads to hypervascular bronchial circulation and vessel rupture
* **Examination**
  * **[Blood] WBC‚Üë, CRP‚Üë (during exacerbations)**: Acute on chronic infection
  * **[Sputum culture] Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae**: Common bacterial colonization in damaged airways
  * **[Pulmonary function tests] FEV1‚Üì, FEV1/FVC ratio‚Üì**: Obstructive pattern due to airway narrowing
  * **[Chest X-ray] Crowded bronchi (tramlines), ring shadows, volume loss**: Structural changes and scarring
  * **[High-resolution CT] Bronchial dilation, bronchial wall thickening, cystic changes**: Gold standard showing structural changes and active infection
* **Management**
  * **Airway clearance techniques (chest physiotherapy, oscillatory devices), mucolytics**: Enhance secretion removal from dilated airways
  * **Bronchodilators (Œ≤2-agonists, anticholinergics)**: Relax airway smooth muscle to improve airflow
  * **Antibiotics (oral for mild exacerbations, IV for severe)**: Treat bacterial infections and reduce inflammation
  * **Anti-inflammatory drugs (inhaled corticosteroids, macrolides)**: Reduce airway inflammation and frequency of exacerbations
{: .notice--info}


## Interstitial Lung Disease / ÈñìË≥™ÊÄßËÇ∫ÁñæÊÇ£

### Idiopathic Pulmonary Fibrosis / ÁâπÁô∫ÊÄßËÇ∫Á∑öÁ∂≠Áóá

* **Overview**
  * Progressive, irreversible fibrotic disease of lung parenchyma of unknown etiology, characterized by usual interstitial pneumonia (UIP) pattern
  * Most common in male adults >50 years old, associated with smoking and environmental exposures
  * Progressive course with median survival of 2-5 years from diagnosis
* **Presentation**
  * **Progressive dyspnea on exertion, eventually at rest**: Fibrosis reduces lung compliance and impairs gas exchange
  * **Dry nonproductive cough**: Irritation from fibrotic changes and distortion of lung architecture
  * **Fine inspiratory crackles**: Opening of fibrotic alveoli during inspiration
  * **Digital clubbing**: Chronic hypoxemia leads to vascular changes in fingertips
* **Examination**
  * **[Blood] LDH‚Üë, KL-6‚Üë, SP-A‚Üë, SP-D‚Üë**: Pneumocyte damage release these biomarkers  
  * **[PFT] FVC‚Üì, FEV1‚Üì, FEV1/FVC normal, DLCO‚Üì**: Restrictive pattern with severe impairment of gas diffusion
  * **[HRCT/Chest X-ray] Honeycombing, traction bronchiectasis, subpleural reticular opacities**: Fibrotic remodeling with cystic spaces and bronchial distortion
  * **[Lung biopsy] Usual interstitial pneumonia pattern with fibroblastic foci**: Heterogeneous fibrosis with active fibroblast proliferation
* **Management**
  * **Antifibrotic agents (pirfenidone, nintedanib)**: Inhibit fibroblast proliferation and collagen synthesis to slow disease progression
  * **Oxygen therapy**: Correct hypoxemia and reduce pulmonary hypertension
  * **Pulmonary rehabilitation**: Improve exercise capacity and quality of life through conditioning
  * **Lung transplantation**: Definitive treatment for end-stage disease in suitable candidates
{: .notice--info}


## Infectious Disease / ÊÑüÊüìÊÄßÁñæÊÇ£

### Bacterial Pneumonia / Á¥∞ËèåÊÄßËÇ∫ÁÇé

* **Overview**
  * Acute infection of lung parenchyma caused by bacterial pathogens (Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa), leading to inflammation and consolidation of alveoli
  * Common in elderly, immunocompromised patients, and those with chronic diseases; can be community-acquired or hospital-acquired
  * Usually responds well to appropriate antibiotic therapy, but can progress to respiratory failure or sepsis if untreated
* **Presentation**
  * **Productive cough with purulent sputum, dyspnea**: Inflammatory exudate in alveoli impairs gas exchange and triggers cough reflex
  * **Fever, chills, malaise**: Systemic inflammatory response to bacterial infection
  * **Pleuritic chest pain**: Irritation of visceral and parietal pleura due to adjacent lung inflammation
  * **Tachypnea, tachycardia**: Compensatory response to hypoxemia and systemic infection
* **Examination**
  * **[Blood] WBC‚Üë, CRP‚Üë, procalcitonin‚Üë**: Markers of bacterial infection and systemic inflammation
  * **[ABG] Hypoxemia, respiratory alkalosis**: Impaired gas exchange and compensatory hyperventilation
  * **[Chest X-ray] Consolidation, air bronchograms**: Inflammatory exudate fills alveolar spaces while bronchi remain air-filled
  * **[CT] Ground-glass opacities, consolidation**: More sensitive detection of inflammatory changes in lung parenchyma
  * **[Sputum culture] Bacterial growth, gram staining**: Identify causative organism and guide antibiotic selection
* **Management**
  * **[Community-acquired] Amoxicillin, ceftriaxone, levofloxacin**: First-line antibiotics for outpatient and hospitalized patients
  * **[Hospital-acquired] Piperacillin-tazobactam, meropenem, vancomycin**: Broad-spectrum coverage for resistant organisms including MRSA and Pseudomonas
  * **[Targeted therapy] Penicillin (S. pneumoniae), cloxacillin (MSSA), vancomycin (MRSA), ceftazidime (Pseudomonas)**: Organism-specific treatment based on culture results
  * **[Supportive care] Oxygen therapy, IV fluids, bronchodilators**: Maintain oxygenation and hydration, improve airway clearance
  * **[Severe cases] Mechanical ventilation, vasopressors**: Support respiratory and circulatory function in respiratory failure or septic shock
{: .notice--info}


### Pulmonary Tuberculosis / ËÇ∫ÁµêÊ†∏

* **Overview**
  * Infection of lungs by Mycobacterium tuberculosis, can be primary infection or reactivation of latent infection
  * More common in immunocompromised patients, developing countries, and elderly
  * Progressive course with potential for cavitation, fibrosis, and dissemination if untreated
* **Presentation**
  * **Persistent cough >3 weeks, hemoptysis**: Chronic inflammation and destruction of lung tissue
  * **Fever, night sweats, weight loss**: Chronic infection and inflammatory cytokine release
  * **Chest pain, dyspnea**: Pleural involvement and reduced lung capacity
* **Examination**
  * **[Blood] ESR‚Üë, CRP‚Üë, anemia**: Chronic inflammation and infection
  * **[Sputum] Acid-fast bacilli, culture positive, PCR positive**: Detection of Mycobacterium tuberculosis
  * **[Chest X-ray] Upper lobe infiltrates, cavitation, lymphadenopathy**: Characteristic pattern of TB infection and tissue destruction
  * **[CT] Tree-in-bud pattern, cavitation, bronchiectasis**: Better visualization of bronchogenic spread and lung damage
  * **[TST/IGRA] Positive**: Cell-mediated immune response to TB antigens
* **Management**
  * **[Initial phase] RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) for 2 months**: Kill actively dividing mycobacteria and prevent resistance
  * **[Continuation phase] RI therapy (Rifampin, Isoniazid) for 4 months**: Eliminate dormant mycobacteria
  * **Directly Observed Therapy (DOT)**: Ensure medication compliance and prevent drug resistance
  * **Respiratory isolation initially**: Prevent airborne transmission until sputum conversion
  * **Contact tracing and screening**: Identify and treat exposed individuals
{: .notice--info}


### COVID-19 / Êñ∞Âûã„Ç≥„É≠„Éä„Ç¶„Ç§„É´„ÇπÊÑüÊüìÁóá

* **Overview**
  * Respiratory infection caused by SARS-CoV-2 virus, highly contagious through respiratory droplets and aerosols
  * Global pandemic since 2019, affects all age groups with higher morbidity and mortality in elderly and immunocompromised individuals
  * Course ranges from asymptomatic infection to severe pneumonia, ARDS, and multi-organ failure
* **Presentation**
  * **Fever, fatigue, myalgia, headache**: Systemic inflammatory response to viral infection
  * **Dry cough, dyspnea, chest pain**: Viral pneumonia and lung inflammation
  * **Loss of taste (ageusia), loss of smell (anosmia)**: Viral damage to olfactory neurons and taste receptors
  * **Diarrhea, nausea, vomiting**: Viral infection of GI tract through ACE2 receptors
  * **[Severe cases] Respiratory distress, hypoxemia**: Cytokine storm leading to ARDS and lung injury
* **Examination**
  * **[PCR/Antigen test] Positive SARS-CoV-2**: Detection of viral RNA or antigens
  * **[Blood] Lymphopenia, CRP‚Üë, D-dimer‚Üë, ferritin‚Üë**: Immune system activation and inflammatory response
  * **[Chest X-ray/CT] Ground-glass opacities, bilateral infiltrates**: Viral pneumonia and inflammatory lung injury
  * **[Pulse oximetry] Decreased oxygen saturation**: Impaired gas exchange due to pneumonia
* **Management**
  * **[Mild cases] Rest, hydration, symptom management**: Allow immune system to clear infection
  * **[Antiviral therapy] Paxlovid (nirmatrelvir/ritonavir), remdesivir**: Inhibit viral replication
  * **[Severe cases] Dexamethasone, tocilizumab**: Reduce inflammatory response and cytokine storm
  * **[Respiratory support] Oxygen therapy, mechanical ventilation, ECMO**: Support gas exchange in severe cases
  * **[Prevention] Vaccination (mRNA, viral vector vaccines), masking, social distancing**: Prevent infection and reduce transmission
{: .notice--info}


## Immune Disease / ÂÖçÁñ´ÊÄßÁñæÊÇ£

### Sarcoidosis / „Çµ„É´„Ç≥„Ç§„Éâ„Éº„Ç∑„Çπ

* **Overview**
  * Multi-system inflammatory disease characterized by non-caseating granulomas in affected organs
  * More common in young adults (20-40 years), higher prevalence in African Americans and Northern Europeans
  * Course varies from acute self-limiting disease to chronic progressive condition with potential for organ fibrosis
* **Presentation**
  * **Asymptomatic (30-50% of cases)**: Incidental finding on chest imaging
  * **Dry cough, dyspnea on exertion, chest tightness**: Pulmonary granulomatous inflammation and fibrosis
  * **Fatigue, weight loss, low-grade fever**: Systemic inflammatory response
  * **Erythema nodosum, lupus pernio**: Granulomatous inflammation of skin and subcutaneous tissue
  * **Blurred vision, eye pain, photophobia**: Granulomatous uveitis
  * **Palpitations, syncope**: Cardiac granulomas causing arrhythmias or conduction blocks
  * **Facial weakness, hearing loss**: Granulomatous involvement of cranial nerves
* **Examination**
  * **[Blood] ACE‚Üë, hypercalcemia, hypercalciuria**: Activated macrophages produce ACE and convert vitamin D to active form
  * **[Chest X-ray/CT] Bilateral hilar lymphadenopathy, pulmonary infiltrates**: Granulomatous inflammation of mediastinal lymph nodes and lung parenchyma
  * **[PFT] Restrictive pattern, reduced DLCO**: Pulmonary fibrosis and impaired gas exchange
  * **[Tissue biopsy] Non-caseating granulomas**: Characteristic histological finding with epithelioid cells and giant cells
  * **[Ophthalmologic exam] Anterior/posterior uveitis**: Granulomatous inflammation of uveal tract
  * **[ECG] AV blocks, ventricular arrhythmias**: Cardiac sarcoidosis affecting conduction system
* **Management**
  * **Observation**: For asymptomatic patients with stable disease
  * **Corticosteroids (prednisolone)**: Suppress granulomatous inflammation and prevent organ damage
  * **Immunosuppressants (methotrexate, azathioprine)**: Steroid-sparing agents for chronic disease or steroid intolerance
  * **Anti-TNF agents (infliximab, adalimumab)**: For refractory cases by blocking key inflammatory cytokine
{: .notice--info}


## Circulatory Disease / Âæ™Áí∞ÊÄßÁñæÊÇ£

### Pulmonary Embolism / ËÇ∫Â°ûÊ†ìÁóá

* **Overview**
  * Blockage of pulmonary arteries by blood clots (usually from deep vein thrombosis), leading to impaired gas exchange
  * Risk factors include immobilization, surgery, cancer, pregnancy, contraceptives, inherited thrombophilia
  * Course ranges from asymptomatic small emboli to massive PE with hemodynamic collapse and death
* **Presentation**
  * **Asymptomatic**: Small peripheral emboli may not cause symptoms
  * **Dyspnea, chest pain (pleuritic), cough, hemoptysis**: Lung tissue ischemia and infarction leading to impaired gas exchange and pleural irritation
  * **Tachycardia, tachypnea**: Compensatory response to hypoxemia and increased physiological dead space
  * **Hypotension, syncope, shock**: Massive PE causing acute right heart failure and reduced cardiac output
* **Examination**
  * **[Blood] D-dimer‚Üë**: Fibrin degradation products from clot formation and breakdown
  * **[ABG] Hypoxemia, hypocapnia, increased A-a gradient**: Ventilation-perfusion mismatch and compensatory hyperventilation
  * **[ECG] S1Q3T3 pattern, right axis deviation, T-wave inversions V1-V4**: Acute right heart strain
  * **[Chest X-ray] Often normal, wedge-shaped opacity, elevated hemidiaphragm**: Pulmonary infarction (Hampton's hump, Westermark sign)
  * **[CT pulmonary angiogram] Filling defects in pulmonary arteries**: Direct visualization of embolic clots
  * **[V/Q scan] Perfusion defects with normal ventilation**: Mismatched ventilation-perfusion
  * **[Echocardiogram] Right heart dilatation, McConnell's sign, tricuspid regurgitation**: Right heart dysfunction from increased pulmonary vascular resistance
* **Management**
  * **[Anticoagulation] Heparin (IV/SC), warfarin, DOACs**: Prevent further clot formation and extension of existing thrombi
  * **[Massive PE] Systemic thrombolysis (tPA), surgical embolectomy, catheter-directed thrombolysis**: Rapidly dissolve or remove clot to restore pulmonary circulation
  * **[IVC filter]**: When anticoagulation contraindicated or recurrent PE despite adequate anticoagulation
  * **[Supportive care] Oxygen therapy, IV fluids, vasopressors**: Maintain oxygenation and hemodynamic stability
{: .notice--info}


### Pulmonary Arterial Hypertension / ËÇ∫ÂãïËÑàÊÄßËÇ∫È´òË°ÄÂúßÁóá

* **Overview**
  * Elevated pulmonary artery pressure due to increased pulmonary vascular resistance from vasoconstriction, remodeling, and thrombosis of small pulmonary arteries
  * Rare disease affecting 15-50 per million population, more common in 30s-40s women
  * Progressive disease leading to right heart failure and death if untreated
* **Presentation**
  * **Dyspnea on exertion, fatigue, exercise intolerance**: Reduced cardiac output and impaired pulmonary gas exchange due to increased pulmonary vascular resistance
  * **Chest pain, syncope**: Right ventricular ischemia and reduced systemic perfusion due to right heart strain
  * **Peripheral edema, ascites, jugular venous distension**: Right heart failure with elevated right-sided filling pressures
* **Examination**
  * **[Blood] BNP/NT-proBNP‚Üë, D-dimer‚Üë**: Right heart failure and potential microthrombi formation
  * **[ECG] Right axis deviation, right ventricular hypertrophy, P pulmonale**: Right heart strain and enlargement
  * **[Echocardiography] RVSP‚Üë (>35 mmHg), right heart enlargement, tricuspid regurgitation**: Elevated pulmonary pressures and right heart dysfunction
  * **[Chest X-ray] Enlarged central pulmonary arteries, peripheral pruning**: Increased pulmonary vascular pressures
  * **[Right heart catheterization] mPAP ‚â•20 mmHg, PCWP ‚â§15 mmHg, PVR >3 Wood units**: Gold standard showing elevated pulmonary pressures with normal left heart pressures
* **Management**
  * **Oxygen therapy (if hypoxic), diuretics, anticoagulation**: Improve oxygenation, reduce fluid overload, prevent thrombosis
  * **Endothelin receptor antagonists (bosentan, ambrisentan)**: Block vasoconstriction and vascular remodeling by inhibiting endothelin-1 pathway
  * **Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)**: Enhance vasodilation by increasing cGMP levels in pulmonary vessels
  * **Prostacyclin analogues (epoprostenol, treprostinil)**: Provide vasodilation and antiproliferative effects through cAMP pathway
  * **Lung transplantation**: Definitive treatment for end-stage disease when medical therapy fails
{: .notice--info}


## Functional Disease / Ê©üËÉΩÊÄßÁñæÊÇ£

### Obstructive Sleep Apnea / ÈñâÂ°ûÊÄßÁù°Áú†ÊôÇÁÑ°ÂëºÂê∏ÁóáÂÄôÁæ§

* **Overview**
  * Repeated collapse of upper airway during sleep due to muscle relaxation and anatomical narrowing, leading to intermittent hypoxemia and sleep fragmentation
  * More common in middle-aged men, strongly associated with obesity
  * Progressive condition that can lead to cardiovascular and metabolic complications if untreated
* **Presentation**
  * **Loud snoring, witnessed apneas**: Upper airway obstruction and intermittent airflow cessation
  * **Excessive daytime sleepiness, fatigue**: Sleep fragmentation and repeated arousals from hypoxemia
  * **Morning headaches**: Nocturnal hypoxemia and hypercapnia leading to cerebral vasodilation
* **Examination**
  * **[Polysomnography] AHI ‚â•5/hour, oxygen desaturations, sleep fragmentation**: Repeated airway obstructions during sleep
  * **[Physical exam] Enlarged tonsils, macroglossia, retrognathia, high BMI**: Anatomical factors contributing to upper airway narrowing
* **Management**
  * **Continuous positive airway pressure (CPAP)**: Pneumatic splinting to maintain upper airway patency
  * **Weight loss, sleep position therapy**: Reduce anatomical obstruction and improve airway stability
  * **Oral appliances (mandibular advancement devices)**: Advance mandible and increase upper airway space
  * **Upper airway surgery (UPPP, genioglossus advancement)**: Remove or reposition anatomical obstructions
{: .notice--info}


## Lung Tumor / ËÇ∫ËÖ´Áòç

### Lung Cancer / ËÇ∫Áôå

* **Overview**
  * Malignant transformation of lung epithelial cells, primarily due to smoking (85-90%), environmental carcinogens (asbestos, radon), and genetic factors
  * **Non-small cell lung cancer (NSCLC) 85%**: Adenocarcinoma (most common, peripheral), squamous cell carcinoma (central, cavitation), large cell carcinoma (poorly differentiated)
  * **Small cell lung cancer (SCLC) 15%**: Highly aggressive, central location, early metastasis, neuroendocrine features  
  * Leading cause of cancer-related death worldwide, predominantly affects smokers and middle-aged to elderly individuals
  * Often diagnosed at advanced stages with poor prognosis due to late symptom onset
* **Presentation**
  * **Persistent cough, dyspnea, chest pain, hemoptysis**: Tumor growth obstructs airways and invades surrounding tissue
  * **Weight loss, fatigue, anorexia**: Cancer cachexia due to increased metabolic demands and inflammatory cytokines
  * **Hoarseness**: Recurrent laryngeal nerve compression by mediastinal lymph nodes
  * **Facial swelling, neck vein distension**: Superior vena cava syndrome due to tumor compression
  * **Bone pain, neurological symptoms**: Metastases to bone, brain, or liver
  * **Clubbing, hyponatremia, hypercalcemia**: Paraneoplastic syndromes from ectopic hormone production
* **Examination**
  * **[Blood] CEA‚Üë, CYFRA21-1‚Üë (NSCLC), NSE‚Üë (SCLC)**: Tumor markers released by cancer cells
  * **[Bronchoscopy] Endobronchial lesion**: Direct visualization of tumor
  * **[Chest X-ray] Pulmonary nodule, mass, pleural effusion**: Direct visualization of tumor or complications
  * **[CT chest] Spiculated mass, lymphadenopathy, pleural thickening**: Detailed tumor characteristics and staging
  * **[PET scan] Increased FDG uptake**: High metabolic activity of malignant cells
  * **[Biopsy] Tissue sampling (bronchoscopy, CT-guided, surgical)**: Histological diagnosis and molecular profiling
* **Management**
  * **[NSCLC Stage I-II] Surgical resection (segmentectomy, lobectomy)**: Complete removal of tumor-containing lung tissue
  * **[NSCLC Stage III] Concurrent chemoradiotherapy**: Combined treatment to control local disease and micrometastases
  * **[NSCLC Stage IV] Systemic chemotherapy (platinum-based doublets)**: Cytotoxic agents target rapidly dividing cancer cells
  * **[NSCLC with mutations] Targeted therapy (EGFR, ALK, ROS1 inhibitors)**: Block specific molecular pathways driving tumor growth
  * **[NSCLC high PD-L1] Immunotherapy (checkpoint inhibitors)**: Enhance immune system recognition and destruction of cancer cells
  * **[SCLC Limited stage] Concurrent chemoradiotherapy**: Chemotherapy with thoracic radiation for localized disease
  * **[SCLC Extensive stage] Systemic chemotherapy + immunotherapy**: Platinum-based chemotherapy with atezolizumab
  * **[Palliative care] Symptom management, radiation for bone metastases**: Improve quality of life and manage complications
{: .notice--info}


## Pleural Disease / ËÉ∏ËÜúÁñæÊÇ£

### Pleural Effusion / ËÉ∏Ê∞¥

* **Overview**
  * Accumulation of fluid in pleural space, classified as transudate (low protein) or exudate (high protein) based on underlying pathophysiology
  * Causes include heart failure, infection, malignancy
  * Course varies from acute to chronic depending on etiology
* **Presentation**
  * **Asymptomatic**: Small effusions may not cause symptoms
  * **Dyspnea, reduced exercise tolerance**: Compression of lung tissue and impaired gas exchange
  * **Pleuritic chest pain, dry cough**: Irritation and inflammation of pleural surfaces
* **Examination**
  * **[Physical] Decreased breath sounds, dullness to percussion, decreased tactile fremitus**: Fluid accumulation dampens sound transmission
  * **[Chest X-ray] Blunting of costophrenic angles, meniscus sign**: Fluid layering in dependent portions of pleural space
  * **[CT] Fluid collection, underlying pathology**: Better visualization of fluid distribution and causative lesions
  * **[Ultrasound] Anechoic fluid collection**: Real-time visualization, guides thoracentesis
  * **[Pleural fluid analysis] Light's criteria, cell count, culture, cytology**: Differentiate transudative vs exudative causes
* **Management**
  * **Thoracentesis**: Diagnostic sampling and symptomatic relief by fluid removal
  * **Chest tube drainage**: For large effusions or empyema to achieve complete drainage
  * **Treatment of underlying cause**: Heart failure management, antibiotics for infection, chemotherapy for malignancy
{: .notice--info}


### Pneumothorax / Ê∞óËÉ∏

* **Overview**
  * Air accumulation in pleural space, causing lung collapse due to rupture of visceral pleura or chest wall injury
  * Primary spontaneous: young, tall, thin males; Secondary spontaneous: patients with underlying lung disease (COPD, asthma); Traumatic: following chest trauma or medical procedures
  * May progress to tension pneumothorax with hemodynamic compromise if untreated
* **Presentation**
  * **Sudden sharp chest pain**: Pleural irritation and stretching of parietal pleura
  * **Shortness of breath**: Reduced lung capacity and impaired gas exchange
  * **Tracheal deviation, jugular vein distension, hypotension**: Tension pneumothorax compresses mediastinum and impairs venous return
* **Examination**
  * **[Physical] Decreased breath sounds, hyperresonance to percussion, reduced chest expansion**: Air in pleural space prevents normal lung expansion and sound transmission
  * **[Chest X-ray] Pleural line, lung collapse, mediastinal shift**: Air-fluid interface visible, lung retraction from chest wall
  * **[CT scan] Pleural air collection, lung atelectasis**: More sensitive detection of small pneumothorax
  * **[ABG] Hypoxemia, respiratory alkalosis**: Impaired gas exchange and compensatory hyperventilation
* **Management**
  * **[Small pneumothorax <20%] Observation, oxygen therapy**: Small air collections may reabsorb spontaneously
  * **[Large pneumothorax >20%] Needle decompression (emergency), chest tube insertion**: Remove trapped air and allow lung re-expansion
  * **[Tension pneumothorax] Immediate needle decompression**: Emergency relief of pressure to prevent cardiovascular collapse
  * **[Recurrent pneumothorax] VATS, pleurodesis**: Surgical repair of blebs and prevention of recurrence by pleural adhesion
{: .notice--info}


## Mediastinal Disease / Á∏¶ÈöîÁñæÊÇ£

## Miscellaneous Respiratory Disease / „Åù„ÅÆ‰ªñ„ÅÆÂëºÂê∏Âô®ÁñæÊÇ£


# Gastroenterology / Ê∂àÂåñÂô®Áßë

# Endocrinology / ÂÜÖÂàÜÊ≥åÁßë

# Nephrology / ËÖéËáìÁßë

# Hematology / Ë°ÄÊ∂≤Áßë

# Rheumatology / „É™„Ç¶„Éû„ÉÅÁßë

# Infectious Diseases / ÊÑüÊüìÁóáÁßë

# Neurology / Á•ûÁµåÁßë

# Psychiatry / Á≤æÁ•ûÁßë

# Ophthalmology / ÁúºÁßë

# Otolaryngology / ËÄ≥ÈºªÂíΩÂñâÁßë

# Dermatology / ÁöÆËÜöÁßë

# Orthopedic Surgery / Êï¥ÂΩ¢Â§ñÁßë

# Urology / Ê≥åÂ∞øÂô®Áßë

# Gynecology / Â©¶‰∫∫Áßë

# Obstetrics / Áî£Áßë

# Pediatrics / Â∞èÂÖêÁßë
